Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LY900010 in Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01160289
Recruitment Status : Completed
First Posted : July 12, 2010
Results First Posted : April 9, 2019
Last Update Posted : April 9, 2019
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Drug: LY2452473 Drug: tadalafil Drug: placebo (tadalafil) Drug: placebo (LY2452473) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 410 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction
Study Start Date : October 2010
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Tadalafil

Arm Intervention/treatment
Experimental: 1 milligram (mg) LY2452473 + 5 mg tadalafil Drug: LY2452473
Administered orally, once daily for 12 weeks

Drug: tadalafil
Administered orally, once daily for 12 weeks

Drug: placebo (tadalafil)
Administered orally, once daily for 12 weeks

Experimental: 5 mg LY2452473 + 5 mg tadalafil Drug: LY2452473
Administered orally, once daily for 12 weeks

Drug: tadalafil
Administered orally, once daily for 12 weeks

Drug: placebo (tadalafil)
Administered orally, once daily for 12 weeks

Experimental: 5 mg LY2452473 + placebo Drug: LY2452473
Administered orally, once daily for 12 weeks

Drug: placebo (tadalafil)
Administered orally, once daily for 12 weeks

Active Comparator: 10 mg tadalafil + placebo Drug: tadalafil
Administered orally, once daily for 12 weeks

Drug: placebo (tadalafil)
Administered orally, once daily for 12 weeks

Drug: placebo (LY2452473)
Administered orally, once daily for 12 weeks

Active Comparator: 5 mg tadalafil + placebo Drug: tadalafil
Administered orally, once daily for 12 weeks

Drug: placebo (tadalafil)
Administered orally, once daily for 12 weeks

Drug: placebo (LY2452473)
Administered orally, once daily for 12 weeks




Primary Outcome Measures :
  1. Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score [ Time Frame: Baseline, Week 12 ]
    The IIEF EF domain score was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF self-reported questionnaire. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.


Secondary Outcome Measures :
  1. Change From Baseline to 12 Week Endpoint in the Percentage of "Yes" Responses on the Sexual Encounter Profile (SEP) Diary [ Time Frame: Baseline, Week 12 ]
    The SEP diary was a participant-assessed diary with 5 questions (Q): Q1 (erection achievement), Q2 (successful penetration), Q3 (successful intercourse), Q4 (satisfied with erection), and Q5 (satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1 to Q5 scores were determined as a percentage of "Yes" responses to each of the 5 questions out of all sexual attempts recorded during the time period. A higher percentage of "Yes" responses indicated better EF. Assessed was the mean change from baseline in the percentage of "Yes" responses to the SEP diary Q1 to Q5. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value <0.25).

  2. Change From Baseline to 12 Week Endpoint in IIEF Domain Scores (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, and Overall Satisfaction) [ Time Frame: Baseline, Week 12 ]
    Intercourse Satisfaction (IS) domain score: sum of Questions (Q) 6, Q7, and Q8, each rated 0 (low/no satisfaction) to 5 (high satisfaction). IS domain score range: 0 to 15; lower scores denoted lower satisfaction. Orgasmic Function (OF) domain score: sum of Q9 and Q10, each rated 0 (no sexual stimulation) to 5 (almost always/always). OF domain score range: 0 to 10; lower scores denoted lower OF. Sexual Desire (SD) domain score: sum of Q11 and Q12, each rated 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). SD domain score range: 2 to 10; lower scores denoted lower SD. Overall Satisfaction (OS) domain score: sum of Q13 and Q14, each rated 1 (low/no satisfaction) to 5 (high satisfaction). OS domain score range: 2 to 10; lower scores denoted lower OS. Least squares (LS) mean estimated from repeated measures analysis of variance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value<0.25).

  3. Change From Baseline to 12 Week Endpoint in the Percentage of Participants Who Return to "Normal" on the International Index of Erectile Function (IIEF) Scale (EF>25) [ Time Frame: Baseline, Week 12 ]
    The percentage of participants whose IIEF Erectile Function (EF) domain scores changed from ≤25 at baseline to >25 (normal) at Week 12. The IIEF EF domain score was the sum of IIEF Question (Q) 1 to Q5 and Q15. Q1 to Q5 were rated 0 (low/no EF) to 5 (high EF) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF.

  4. Change From Baseline to 12 Week Endpoint in IIEF EF Domain Score Reported by Testosterone Concentration Subgroups [ Time Frame: Baseline, Week 12 ]
    The International Index of Erectile Function (IIEF) EF was the sum of Questions (Q) 1 to Q5 and Q15 of the IIEF Self-reported questionnaire. Q1 to Q5 were rated 0 (low/no erectile function) to 5 (high erectile function) and Q15 was rated 1 (no/low confidence) to 5 (high confidence). IIEF EF domain scores ranged from 1 to 30. Higher scores denoted better EF. Testosterone concentration subgroups were based on optimal baseline testosterone levels (<340 nanograms per deciliter [ng/dL] or ≥340 ng/dL). The least squares (LS) mean was estimated from an analysis of covariance (ANCOVA) model that included terms for treatment group, baseline, and baseline*treatment interaction (if p-value<0.25).

  5. Change From Baseline to 12 Week Endpoint in Prostate-Specific Antigen (PSA) [ Time Frame: Baseline, Week 12 ]
    The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value<0.25).

  6. Change From Baseline to 12 Week Endpoint in Total Cholesterol and Triglycerides [ Time Frame: Baseline, Week 12 ]
    The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value<0.25).

  7. Percent Change From Baseline to 12 Week Endpoint in High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C) [ Time Frame: Baseline, Week 12 ]
    The least squares (LS) was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value<0.25).

  8. Change From Baseline to 12 Week Endpoint in Fasting Glucose [ Time Frame: Baseline, Week 12 ]
    The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value<0.25).

  9. Change From Baseline to 12 Week Endpoint in Fasting Insulin [ Time Frame: Baseline, Week 12 ]
    Change from baseline to 12 Week endpoint in fasting blood insulin concentration. The least squares (LS) mean was estimated from a repeated measures analysis of covariance model that included terms for treatment, visit, treatment*visit, baseline, baseline*treatment (if p-value<0.25).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria include:

  • Ambulatory men
  • History of erectile dysfunction of at least 3 months duration
  • History of incomplete response to any phosphodiesterase type 5 inhibitor (PDE5i) at the maximum tolerated dose within the label
  • Anticipate having the same female sexual partner throughout the duration of the study
  • Are willing and able to make at least 4 sexual intercourse attempts with the female sexual partner during each 4-week segment of the study
  • Agree to use birth control during the study and for 60 days after the study, unless the female partner is postmenopausal
  • Agree not to use any other erectile dysfunction treatment, including herbal treatment, during the study and for 96 hours after the last dose of study drug
  • Screening laboratory tests within normal limits except for testosterone
  • Without a language barrier, are reliable and willing to follow study procedures
  • Prostate-specific antigen (PSA) less than 10 nanograms per milliliter (ng/ml). Men with PSA greater than 4 and less than 10 ng/ml must have documentation of a negative histological biopsy of carcinoma of prostate within 12 months prior to screening

Exclusion Criteria include:

  • History of penile implant
  • History of no response to injection therapy for erectile dysfunction
  • History of radical prostatectomy or other pelvic surgery with subsequent failure to achieve any erection
  • Exhibit the presence of clinically significant penile deformity in the opinion of the investigator
  • History of prior sexual legal convictions
  • Bilateral hip replacements
  • History of cancer within the previous 5 years, except for excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin
  • Chronic stable angina currently treated with long-acting nitrates
  • Chronic stable angina requiring treatment with short-acting nitrates within 90 days prior to screening
  • Angina occurring during sexual intercourse in the 6 months prior to screening
  • Unstable angina within 6 months prior to screening
  • Myocardial infarction or coronary artery bypass graft surgery within 90 days prior to screening
  • Angioplasty or stent placement within 90 days prior to screening
  • Congestive heart failure within 6 months prior to screening
  • History of sudden cardiac arrest
  • Supraventricular arrhythmia with an uncontrolled ventricular response at rest, or any history of spontaneous or induced sustained ventricular tachycardia, or use an automatic internal cardioverter-defibrillator
  • An abnormality in the 12-lead electrocardiogram (ECG) that in the opinion of the investigator places the subject in an unacceptable risk for study participation
  • Systolic blood pressure greater than 170 or less than 90 millimeters of mercury (mm Hg) or diastolic blood pressure greater than 100 or less than 50 mm Hg at screening
  • Hepatic, renal, human immunodeficiency virus (HIV), or clinically significant active neuropsychiatric disease
  • History of central nervous system injuries (including stroke or spinal cord injury) within 6 months prior to screening
  • Alcohol intake of 5 units or greater per day (1 unit = 12 ounces beer, 5 ounces wine, or 1.5 ounces of 80-proof distilled spirits)
  • Receiving treatment with antiandrogens or 5-alpha reductase inhibitor
  • Anabolic steroids, calcitonin, oral bisphosphonates, Vitamin D greater than 50,000 international units per week (IU/week), dehydroepiandrosterone (DHEA), steroidal supplements, nutritional products intended to have weight reduction or performance enhancing effects, herbal supplements within 7 days prior to screening
  • Currently treated with a potent cytochrome P450 (CYP) 3A4 inhibitor, such as systemic ketoconazole or ritonavir, or a CYP3A4 inducer such as rifampicin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01160289


  Show 36 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01160289     History of Changes
Other Study ID Numbers: 11888
I4K-MC-GPEC ( Other Identifier: Eli Lilly and Company )
First Posted: July 12, 2010    Key Record Dates
Results First Posted: April 9, 2019
Last Update Posted: April 9, 2019
Last Verified: March 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Tadalafil
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents